Novel therapeutic interventions for combating Parkinson's disease and prospects of Nose-to-Brain drug delivery

Biochem Pharmacol. 2022 Jan:195:114849. doi: 10.1016/j.bcp.2021.114849. Epub 2021 Nov 19.

Abstract

Parkinson disease (PD) is a progressive neurodegenerative disorder prevalent mainly in geriatric population. While, L-DOPA remains one of the major choices for the therapeutic management of PD, various motor and non-motor manifestations complicate the management of PD. In the last two decades, exhaustive research has been carried out to explore novel therapeutic approaches for mitigating motor and non-motor symptoms of PD. These approaches majorly include receptor-based, anti-inflammatory, stem-cell and nucleic acid based. The major limitations of existing therapeutic interventions (of commonly oral route) are low efficacy due to low brain bioavailability and associated side effects. Nanotechnology has been exploited and has gained wide attention in the recent years as an approach for enhancement of bioavailability of various small molecule drugs in the brain. To address the challenges associated with PD therapy, nose-to-brain delivery utilizing nanomedicine-based approaches has been found to be encouraging in published evidence. Therefore, the present work summarises the major challenges and limitations with antiparkinsonian drugs, novel therapeutic interventions, and scope of nanomedicine-based nose-to-brain delivery in addressing the current challenges of antiparkinsonian therapy. The manuscript tries to sensitize the researchers for designing brain-targeted nanomedicine loaded with natural/synthetic scaffolds, biosimilars, and nucleic acids that can bypass the first-pass effect for the effective management of PD.

Keywords: Dopamine; Nanomedicine; Nose-to-brain delivery; Nucleic acid therapy; Parkinson's disease; Stem cell therapy; Viral vector-mediated delivery.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antiparkinson Agents / administration & dosage
  • Antiparkinson Agents / pharmacokinetics
  • Antiparkinson Agents / therapeutic use*
  • Biological Availability
  • Biosimilar Pharmaceuticals / administration & dosage
  • Biosimilar Pharmaceuticals / pharmacokinetics
  • Biosimilar Pharmaceuticals / therapeutic use*
  • Brain / metabolism*
  • Drug Delivery Systems / methods
  • Humans
  • Nanomedicine / methods
  • Nasal Mucosa / metabolism*
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / metabolism

Substances

  • Antiparkinson Agents
  • Biosimilar Pharmaceuticals